Vertex (VRTX) Orkambi Briefing Docs 'Positive Overall', Baird Says

Baird analyst Brian Skorney weighed in on Outperform-rated Vertex (NASDAQ: VRTX) after the FDA briefing docs on Orkambi. While not benign he said they look positive overall.

"The FDA review of the lumacaftor/ivacaftor combo didn't yield any smoking gun and generally looks in line with expectations," Skorney said. "We expect the panel next Tuesday to vote in favor of approval even though they are likely vocalize a desire to see a greater clinical effect."

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $125.05 yesterday.

You May Also Be Interested In

• Barclays Upgrades Crown Castle (CCI) to Overweight
• Jefferies Starts Bajaj Housing Finance (BAJAJHFL:IN) at Hold
• Jefferies Starts Trekor Metals (TKO:CN) (TGB) at Buy